Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE -- Ignore unavailable to you. Want to Upgrade?

To: Coha who wrote (388)	7/7/1998 8:40:00 AM
From: Douglas	Read Replies (1) \| Respond to of 670

Wound Care Maturing Into the Fastest-Growing Biotechnology Sector, Analyst Says LOS ANGELES--(BW HealthWire)--July 7, 1998--Wound care has become ''a major target of biotechnology companies,'' according to an analyst covering this sector. The entire wound care biotechnology sector has been broken down, described and rated in a newly released research report. Alexander K. Arrow, vice president, research at Wedbush Morgan Securities in Los Angeles, has issued a report describing companies competing in each of 11 different sub-sectors of the wound care market. The markets include the diabetic foot ulcer market, the severe burn market, the emergency room wound-closing glue market and eight others. According to the report, each one is serving as a battleground for companies developing competing wound care products From the rivalry between Organogenesis Inc. [AMEX:ORG - news] and Ortec International over artificial skin for venous ulcers, to the battle between Closure Medical Corp. [Nasdaq:CLSR - news] and MedLogic Global Corp. over wound closure glues, the report analyzes the relative strengths and weaknesses of each wound care company. The report then goes on to rank each company's position in its market according to three parameters: the strength of its product, the stage of its development and the effectiveness of its distribution system. The report also offers investment recommendations on four companies on the Wedbush Morgan wound care research list. Arrow's report highlights and compares a total of 36 companies (28 public and eight private) in this industry segment. The public wound care companies included are: Advanced Tissue Sciences (ATIS), BioSpecifics Corp. (BSTC), Carrington Laboratories (CARN), Chiron Corp. (Nasdaq:CHIR - news), Closure Medical Corp. (CLSR), Cryolife (CRY), Curative Health Services (CURE), Cypros Pharmaceuticals (CYP) and Datascope Corp. (Nasdaq:DSCP - news). Also, Derma Sciences (DSCI), Focal (FOCL), Fusion Medical Technologies (FSON), Genzyme Tissue Repair (GENZL), Gliatech (GLIA), Human Genome Sciences (HGSI), Integra LifeSciences (IART), Johnson & Johnson (JNJ), Kensey Nash (KNSY), Life Medical Sciences (CHAI), LifeCell Corp. (LIFC). Also, Lifecore Biomedical (LCBM), Magainin Pharmaceuticals (MAGN), Organogenesis (ORG), Ortec International (ORTC), Perclose (PERC), ProCyte Corp. (Nasdaq:PRCY - news), Protein Polymer Technologies (PPTI) and Thermogenesis (KOOL). Larger companies with collaborations in wound care detailed in the report include: Baxter Healthcare (BAX), Bristol-Myers Squibb (BMS), Johnson & Johnson (JNJ), Novartis (NVTSY), Tyco International (TYC) and 3M Corp. (MMM). NOTE TO EDITORS: To find out about receiving a copy of the report, contact a Wedbush Morgan sales representative. Dr. Arrow's office is 213/688-4521.